First Header Logo Second Header Logo

Connection

Dalane Kitzman to Obesity

Back to Details
This is a "connection" page, showing publications Dalane Kitzman has written about Obesity.
Dalane Kitzman
Connection Strength
6.373
Obesity
  1. Pandey A, Lewis GD, Borlaug BA, Shah SJ, Sauer AJ, Litwin S, Sharma K, Jorkasky DK, Tarka EA, Khan SM, Kitzman DW. Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial. JAMA Cardiol. 2025 Jun 01; 10(6):609-616.
    View in: PubMed
    Score: 0.537
  2. Upadhya B, Brubaker PH, Nicklas BJ, Houston DK, Haykowsky MJ, Kitzman DW. Long-term Changes in Body Composition and Exercise Capacity Following Calorie Restriction and Exercise Training in Older Patients with Obesity and Heart Failure With Preserved Ejection Fraction. J Card Fail. 2025 Mar; 31(3):497-507.
    View in: PubMed
    Score: 0.504
  3. Kitzman DW, Lewis GD, Pandey A, Borlaug BA, Sauer AJ, Litwin SE, Sharma K, Jorkasky DK, Khan S, Shah SJ. A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial. Eur J Heart Fail. 2024 Sep; 26(9):2013-2024.
    View in: PubMed
    Score: 0.504
  4. Haykowsky MJ, Nicklas BJ, Brubaker PH, Hundley WG, Brinkley TE, Upadhya B, Becton JT, Nelson MD, Chen H, Kitzman DW. Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2018 08; 6(8):640-649.
    View in: PubMed
    Score: 0.333
  5. Packer M, Kitzman DW. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. JACC Heart Fail. 2018 08; 6(8):633-639.
    View in: PubMed
    Score: 0.325
  6. Kitzman DW, Haykowsky MJ, Kraus W. Diet and Exercise for Obese Patients With Heart Failure--Reply. JAMA. 2016 Jun 21; 315(23):2619-20.
    View in: PubMed
    Score: 0.289
  7. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, Eggebeen J, Nicklas BJ. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016 Jan 05; 315(1):36-46.
    View in: PubMed
    Score: 0.280
  8. Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2015 Jun; 12(3):205-14.
    View in: PubMed
    Score: 0.269
  9. Pandey A, Moroney M, Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Petrie MC, Rönnbäck C, Domdey A, Rasmussen S, Chinnakondepalli KM, Patel S, Kosiborod MN. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. Eur J Heart Fail. 2025 Nov; 27(11):2537-2543.
    View in: PubMed
    Score: 0.139
  10. Borlaug BA, Kitzman DW, Patel S, Chinnakondepalli KM, Butler J, Davies MJ, Petrie MC, Shah SJ, Verma S, Núñez J, Einfeldt MN, Liisberg K, Salsali A, Kosiborod MN. Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. JACC Heart Fail. 2025 Nov; 13(11):102660.
    View in: PubMed
    Score: 0.137
  11. Pandey A, Kitzman DW, Chinnakondepalli KM, Patel S, Borlaug BA, Butler J, Davies MJ, Shah SJ, Verma S, Rönnbäck C, Domdey A, Liisberg K, Schou M, Perna E, Ahmed FZ, Fu M, Petrie MC, Kosiborod MN. Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. JACC Heart Fail. 2025 Oct; 13(10):102610.
    View in: PubMed
    Score: 0.137
  12. Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):196-209.
    View in: PubMed
    Score: 0.131
  13. Shah SJ, Sharma K, Borlaug BA, Butler J, Davies M, Kitzman DW, Petrie MC, Verma S, Patel S, Chinnakondepalli KM, Einfeldt MN, Jensen TJ, Rasmussen S, Asleh R, Ben-Gal T, Kosiborod MN. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024 Sep 14; 45(35):3254-3269.
    View in: PubMed
    Score: 0.128
  14. Verma S, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Rönnbäck C, Abildstrøm SZ, Liisberg K, Wolf D, von Lewinski D, Lelonek M, Melenovsky V, Senni M, Kosiborod MN. Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22; 84(17):1646-1662.
    View in: PubMed
    Score: 0.127
  15. Verma S, Butler J, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Jensen TJ, Rasmussen S, Rönnbäck C, Merkely B, O'Keefe E, Kosiborod MN. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program. J Am Coll Cardiol. 2024 Oct 22; 84(17):1603-1614.
    View in: PubMed
    Score: 0.127
  16. Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Verma S, Abildstrøm SZ, Nygaard Einfeldt M, Rasmussen S, Abhayaratna WP, Ahmed FZ, Ben-Gal T, Chopra V, Ito H, Merkely B, Núñez J, Senni M, van der Meer P, Wolf D, Petrie MC, Kosiborod MN. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. J Am Coll Cardiol. 2024 Oct 22; 84(17):1587-1602.
    View in: PubMed
    Score: 0.127
  17. Verma S, Butler J, Borlaug BA, Davies M, Kitzman DW, Shah SJ, Petrie MC, Barros E, Rönnbäck C, Vestergaard LS, Schou M, Ezekowitz JA, Sharma K, Patel S, Chinnakondepalli KM, Kosiborod MN. Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials. J Am Coll Cardiol. 2024 Aug 27; 84(9):773-785.
    View in: PubMed
    Score: 0.126
  18. Schou M, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Patel S, Chinnakondepalli KM, Harring S, Abildstrøm SZ, Liisberg K, Kosiborod MN. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program. J Am Coll Cardiol. 2024 Jul 16; 84(3):247-257.
    View in: PubMed
    Score: 0.126
  19. Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K, Ezekowitz JA, Fu M, Melenovský V, Ito H, Lelonek M, Kosiborod MN. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. J Am Coll Cardiol. 2024 Jul 02; 84(1):27-40.
    View in: PubMed
    Score: 0.125
  20. Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024 Apr 27; 403(10437):1635-1648.
    View in: PubMed
    Score: 0.124
  21. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024 Apr 18; 390(15):1394-1407.
    View in: PubMed
    Score: 0.124
  22. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21; 389(12):1069-1084.
    View in: PubMed
    Score: 0.119
  23. Brubaker PH, Nelson WB, Kitzman DW. Response by Brubaker et al to Letter Regarding "A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction". Circ Heart Fail. 2023 May; 16(5):e010419.
    View in: PubMed
    Score: 0.116
  24. Samuel TJ, Kitzman DW, Haykowsky MJ, Upadhya B, Brubaker P, Nelson MB, Hundley WG, Nelson MD. Left ventricular diastolic dysfunction and exercise intolerance in obese heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2021 04 01; 320(4):H1535-H1542.
    View in: PubMed
    Score: 0.100
  25. Ahmadi S, Razazan A, Nagpal R, Jain S, Wang B, Mishra SP, Wang S, Justice J, Ding J, McClain DA, Kritchevsky SB, Kitzman D, Yadav H. Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. J Gerontol A Biol Sci Med Sci. 2020 06 18; 75(7):e9-e21.
    View in: PubMed
    Score: 0.095
  26. Pandey A, Patel KV, Bahnson JL, Gaussoin SA, Martin CK, Balasubramanyam A, Johnson KC, McGuire DK, Bertoni AG, Kitzman D, Berry JD. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial. Circulation. 2020 04 21; 141(16):1295-1306.
    View in: PubMed
    Score: 0.093
  27. Kitzman DW, Upadhya B, Brubaker PH, Haykowsky MJ, Nelson MD. Reply: Heart Failure With Preserved Ejection Fraction: Types 1 and 2? JACC Heart Fail. 2019 07; 7(7):632-633.
    View in: PubMed
    Score: 0.089
  28. Ramalho SHR, Santos M, Claggett B, Matsushita K, Kitzman DW, Loehr L, Solomon SD, Skali H, Shah AM. Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study. JAMA Netw Open. 2019 06 05; 2(6):e195321.
    View in: PubMed
    Score: 0.089
  29. Kitzman DW, Nicklas BJ. Pivotal Role of Excess Intra-Abdominal Adipose in the Pathogenesis of Metabolic/Obese HFpEF. JACC Heart Fail. 2018 12; 6(12):1008-1010.
    View in: PubMed
    Score: 0.085
  30. Kitzman DW, Lam CSP. Obese Heart Failure With Preserved Ejection Fraction Phenotype: From Pariah to Central Player. Circulation. 2017 07 04; 136(1):20-23.
    View in: PubMed
    Score: 0.078
  31. Bello NA, Cheng S, Claggett B, Shah AM, Ndumele CE, Roca GQ, Santos AB, Gupta D, Vardeny O, Aguilar D, Folsom AR, Butler KR, Kitzman DW, Coresh J, Solomon SD. Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). Circ Heart Fail. 2016 08; 9(8).
    View in: PubMed
    Score: 0.073
  32. Kitzman DW, Shah SJ. The HFpEF Obesity Phenotype: The Elephant in the Room. J Am Coll Cardiol. 2016 07 12; 68(2):200-3.
    View in: PubMed
    Score: 0.073
  33. Neiberg RH, Wing RR, Bray GA, Reboussin DM, Rickman AD, Johnson KC, Kitabchi AE, Faulconbridge LF, Kitzman DW, Espeland MA. Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study. Obesity (Silver Spring). 2012 Oct; 20(10):2048-56.
    View in: PubMed
    Score: 0.053
  34. Shea MK, Nicklas BJ, Houston DK, Miller ME, Davis CC, Kitzman DW, Espeland MA, Appel LJ, Kritchevsky SB. The effect of intentional weight loss on all-cause mortality in older adults: results of a randomized controlled weight-loss trial. Am J Clin Nutr. 2011 Sep; 94(3):839-46.
    View in: PubMed
    Score: 0.051
  35. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May; 4(3):324-31.
    View in: PubMed
    Score: 0.050
  36. Shea MK, Houston DK, Nicklas BJ, Messier SP, Davis CC, Miller ME, Harris TB, Kitzman DW, Kennedy K, Kritchevsky SB. The effect of randomization to weight loss on total mortality in older overweight and obese adults: the ADAPT Study. J Gerontol A Biol Sci Med Sci. 2010 May; 65(5):519-25.
    View in: PubMed
    Score: 0.046
  37. Arena R, Myers J, Abella J, Pinkstaff S, Brubaker P, Moore B, Kitzman D, Peberdy MA, Bensimhon D, Chase P, Forman D, West E, Guazzi M. Influence of etiology of heart failure on the obesity paradox. Am J Cardiol. 2009 Oct 15; 104(8):1116-21.
    View in: PubMed
    Score: 0.045
  38. Nicklas BJ, Cesari M, Penninx BW, Kritchevsky SB, Ding J, Newman A, Kitzman DW, Kanaya AM, Pahor M, Harris TB. Abdominal obesity is an independent risk factor for chronic heart failure in older people. J Am Geriatr Soc. 2006 Mar; 54(3):413-20.
    View in: PubMed
    Score: 0.035
  39. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, Emerson SS, Kahn SE, Kitzman DW, Lingvay I, Mahaffey KW, Petrie MC, Plutzky J, Rasmussen S, Rönnbäck C, Shah SJ, Verma S, Weeke PE, Lincoff AM. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024 Sep 07; 404(10456):949-961.
    View in: PubMed
    Score: 0.032
  40. Litwin SE, Komtebedde J, Seidler T, Borlaug BA, Winkler S, Solomon SD, Eicher JC, Mazimba S, Khawash R, Sverdlov AL, Hummel SL, Bugger H, Boenner F, Hoendermis E, Cikes M, Demers C, Silva G, van Empel V, Starling RC, Penicka M, Cutlip DE, Leon MB, Kitzman DW, van Veldhuisen DJ, Shah SJ. Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial. Eur J Heart Fail. 2024 Jan; 26(1):177-189.
    View in: PubMed
    Score: 0.030
  41. Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H, Schou M, Melenovský V, Abhayaratna W, Kitzman DW. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2024 Jan 16; 149(3):204-216.
    View in: PubMed
    Score: 0.030
  42. Butler J, Abildstrøm SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Verma S, Abhayaratna WP, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Núñez J, Perna E, Schou M, Senni M, van der Meer P, von Lewinski D, Wolf D, Altschul RL, Rasmussen S, Kosiborod MN. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023 Nov 28; 82(22):2087-2096.
    View in: PubMed
    Score: 0.030
  43. Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Dhingra NK, Kosiborod MN. A big STEP for treatment of heart failure with preserved ejection fraction. Cell Metab. 2023 Oct 03; 35(10):1681-1687.
    View in: PubMed
    Score: 0.030
  44. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Møller DV, Petrie MC, Shah SJ, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Núñez J, Perna E, Schou M, Senni M, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023 Sep; 29(9):2358-2365.
    View in: PubMed
    Score: 0.030
  45. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023 Aug; 11(8 Pt 1):1000-1010.
    View in: PubMed
    Score: 0.029
  46. Mishra SP, Wang B, Jain S, Ding J, Rejeski J, Furdui CM, Kitzman DW, Taraphder S, Brechot C, Kumar A, Yadav H. A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut. Gut. 2023 Oct; 72(10):1848-1865.
    View in: PubMed
    Score: 0.029
  47. Houston DK, Miller ME, Kitzman DW, Rejeski WJ, Messier SP, Lyles MF, Kritchevsky SB, Nicklas BJ. Long-Term Effects of Randomization to a Weight Loss Intervention in Older Adults: A Pilot Study. J Nutr Gerontol Geriatr. 2019 Jan-Mar; 38(1):83-99.
    View in: PubMed
    Score: 0.022
  48. Ahmadi S, Nagpal R, Wang S, Gagliano J, Kitzman DW, Soleimanian-Zad S, Sheikh-Zeinoddin M, Read R, Yadav H. Prebiotics from acorn and sago prevent high-fat-diet-induced insulin resistance via microbiome-gut-brain axis modulation. J Nutr Biochem. 2019 05; 67:1-13.
    View in: PubMed
    Score: 0.022
  49. Espeland MA, Dutton GR, Neiberg RH, Carmichael O, Hayden KM, Johnson KC, Jeffery RW, Baker LD, Cook DR, Kitzman DW, Rapp SR. Impact of a Multidomain Intensive Lifestyle Intervention on Complaints About Memory, Problem-Solving, and Decision-Making Abilities: The Action for Health in Diabetes Randomized Controlled Clinical Trial. J Gerontol A Biol Sci Med Sci. 2018 10 08; 73(11):1560-1567.
    View in: PubMed
    Score: 0.021
  50. Fernandes-Silva MM, Shah AM, Hegde S, Goncalves A, Claggett B, Cheng S, Nadruz W, Kitzman DW, Konety SH, Matsushita K, Mosley T, Lam CS, Borlaug BA, Solomon SD. Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study. JACC Heart Fail. 2017 03; 5(3):157-165.
    View in: PubMed
    Score: 0.019
  51. Bertoni AG, Wagenknecht LE, Kitzman DW, Marcovina SM, Rushing JT, Espeland MA. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012 Jul; 20(7):1511-8.
    View in: PubMed
    Score: 0.013
  52. Horwich TB, Broderick S, Chen L, McCullough PA, Strzelczyk T, Kitzman DW, Fletcher G, Safford RE, Ewald G, Fine LJ, Ellis SJ, Fonarow GC. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. Am J Cardiol. 2011 Dec 15; 108(12):1754-9.
    View in: PubMed
    Score: 0.013
  53. de Simone G, Kitzman DW, Chinali M, Oberman A, Hopkins PN, Rao DC, Arnett DK, Devereux RB. Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J. 2005 May; 26(10):1039-45.
    View in: PubMed
    Score: 0.008
  54. de Simone G, Devereux RB, Palmieri V, Bella JN, Oberman A, Kitzman DW, Hopkins PN, Rao DC, Arnett DK. Influence of fat-free mass on detection of appropriateness of left ventricular mass: the HyperGEN Study. J Hypertens. 2003 Sep; 21(9):1747-52.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.